Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $6.7700 (-0.59%) ($6.7700 - $6.7700) on Fri. Jul. 2, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 8.5% (three month average) | RSI | 34 | Latest Price | $6.7700(-0.59%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -1.2% a day on average for past five trading days. | Weekly Trend | HTBX declines -2% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(54%) ARKG(52%) ARKK(51%) IBUY(49%) IPO(47%) | Factors Impacting HTBX price | HTBX will decline at least -4.25% in a week (0% probabilities). VIXM(-32%) VXX(-28%) UUP(-14%) TLT(-12%) XLU(-10%) | | | | | Relative Volatility | | | | Market Trend Strength | -4.25% (StdDev 8.5%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.18 | 5 Day Moving Average | $6.85(-1.17%) | 10 Day Moving Average | $6.95(-2.59%) | 20 Day Moving Average | $7.18(-5.71%) | To recent high | -37% | To recent low | 16.3% | Market Cap | $745m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |